AIM Japan Announces Clinical Validity of Bone Mineral Density Estimation Technology Using AI Analysis of Plain X-ray Images

Release Overview

AIM Japan K.K., the Japanese subsidiary of Alpha Intelligence Manifolds, Inc. (AIM), held a co-sponsored seminar and corporate exhibition at the 28th Annual Meeting of the Japanese Osteoporosis Society, held from September 11 to 13, 2026, presenting the potential of AI applications in osteoporosis treatment. The society featured presentations of research results using Japanese clinical data and a technical lecture by a specialist from Taiwan.

Details of the Presented Technology

The focus of the presentation was AI image analysis technology utilizing plain X-ray images captured during routine medical examinations. In particular, comparative evaluation results with the DXA method were reported regarding research on estimating bone mineral density (BMD) from lumbar spine and hip joint images. Furthermore, research and development initiatives analyzing both bone and skeletal muscle under the concept of "one scan, two screenings" were introduced.

Technical Background and Clinical Significance

AIM's technology aims to enable the early evaluation of osteoporosis and sarcopenia by routing existing plain X-ray images for analysis without significantly altering established clinical workflows. In addition to "DeepXray™ Spina," which has already obtained regulatory approval overseas, the accumulation of academic evidence is progressing in Japan through joint research with the Tohoku University Hospital AI Lab and other institutions.

Future Outlook and Roadmap

AIM will continue to deepen academic collaborations with domestic universities and medical institutions, pursuing ongoing validation based on Japanese clinical data. Additionally, through partnerships with medical device manufacturers and healthcare IT companies, the company aims to build implementation models for existing medical systems and imaging infrastructure, providing new added value to clinical settings.